237 related articles for article (PubMed ID: 34822814)
1. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
Dixit G; Prabhu A
Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
[TBL] [Abstract][Full Text] [Related]
2. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
3. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
Menendez-Gutierrez MP; Roszer T; Ricote M
Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
[TBL] [Abstract][Full Text] [Related]
4. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
Tan CK; Zhuang Y; Wahli W
Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
[TBL] [Abstract][Full Text] [Related]
5. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
[TBL] [Abstract][Full Text] [Related]
7. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.
Cheng HS; Tan WR; Low ZS; Marvalim C; Lee JYH; Tan NS
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614690
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
9. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.
Laganà AS; Vitale SG; Nigro A; Sofo V; Salmeri FM; Rossetti P; Rapisarda AM; La Vignera S; Condorelli RA; Rizzo G; Buscema M
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347932
[TBL] [Abstract][Full Text] [Related]
11. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
12. PPARs as targets for metabolic and cardiovascular diseases.
Cheng PT; Mukherjee R
Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Giaginis C; Tsantili-Kakoulidou A; Theocharis S
Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
[TBL] [Abstract][Full Text] [Related]
14. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
15. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
16. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
Cheang WS; Tian XY; Wong WT; Huang Y
Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
[TBL] [Abstract][Full Text] [Related]
17. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
Feldman PL; Lambert MH; Henke BR
Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
[TBL] [Abstract][Full Text] [Related]
18. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.
Peters JM; Shah YM; Gonzalez FJ
Nat Rev Cancer; 2012 Feb; 12(3):181-95. PubMed ID: 22318237
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Friedmann PS; Cooper HL; Healy E
Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Gervois P; Fruchart JC; Staels B
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
